Free Trial Information
BioCentury | Feb 22, 2021
Product Development

Otonomy looking beyond Meniere disease after latest Phase III miss

Otonomy will look ahead to a pipeline addressing tinnitus and hearing loss after its latest Phase III failure in Meniere disease.  With Monday’s readout, Otonomy Inc. (NASDAQ:OTIC) shares fell $2.39 (44%) to $3.00, cutting the...
Read More
BioCentury | Oct 4, 2019
Finance

Biotech down again in 3Q19

...Source: Yahoo! Finance The biggest loss among the small calls was the 90% plunge by Neurotrope Inc....
...Editor, Data & Analytics Sarepta Therapeutics Inc. Genmab A/S Galapagos N.V. Nektar Therapeutics Shenzhen Chipscreen Biosciences Ltd. Clovis Oncology Inc. Opthea Ltd. Transgene S.A. Neurotrope Inc. Deciphera...
Read More
BioCentury | Sep 9, 2019
Clinical News

Sept. 9 Clinical Quick Takes: Translate to discontinue enzyme deficiency candidate; plus Janssen, Neurotrope, AMT and Cassava

...in Denmark. Spravato is approved for treatment-resistant depression. Neurotrope plummets on Phase II Alzheimer’s failure Neurotrope Inc....
...kinase C ε Sandi Wong, Staff Writer MRT5201 PTI-125 Spravato, esketamine (jnj-54135419) Synthetic Bryostatin-1 Applied Molecular Transport LLC Cassava Sciences Inc. Janssen Johnson & Johnson Neurotrope Inc. Translate...
Read More
BioCentury | Feb 28, 2018
Distillery Therapeutics

Autoimmune disease

...models of MS and seeking industry partners to test the compound in progressive MS patients. Neurotrope Inc....
...testing to treat Alzheimer’s disease and preclinical testing to treat Niemann-Pick disease type C (NPC). Neurotrope...
Read More
BioCentury | Feb 23, 2018
Emerging Company Profile

Cutting viruses

Armed with a suite of CRISPR nucleases and multiple guide RNAs, Excision BioTherapeutics Inc. is using gene editing to cut out integrated latent viruses from host genomes. The newco is starting with HIV, but has...
Read More
BioCentury | Feb 1, 2018
Preclinical News

Zika-related viruses could also lead to fetal demise

In a study published in Science Translational Medicine , researchers at Washington University School of Medicine in St. Louis and colleagues found that two Zika-related viruses infected human placental explants and led to fetal demise in...
Read More
BioCentury | Dec 20, 2017
Company News

Management tracks: Intellia, Spectrum

...Hamilton as CEO. He succeeds Gary Jacob, who will serve as executive chairman. Neurology company Neurotrope Inc....
Read More
BioCentury | Oct 17, 2017
Distillery Techniques

Chemistry

...and 1.4 nM. Next steps include using the method to synthesize additional undisclosed bryostatin-1 analogs. Neurotrope Inc....
...to treat Alzheimer’s disease and in preclinical testing to treat Niemann-Pick disease type C (NPC). Neurotrope...
...kinase C (PKC) modulator bryostatin-1 and its analogs LICENSING STATUS: Patent application filed; licensed to Neurotrope Inc....
Read More
BioCentury | Jun 5, 2017
Clinical News

Zika virus hijacks neurodevelopmental protein to replicate

In a paper published in Science , University of Cambridge researchers show the Zika virus hijacks neurodevelopmental protein Musashi RNA-binding protein 1 (MSI1) in neural stem cells, increasing viral replication and preventing neural stem cell function....
Read More
BioCentury | May 5, 2017
Clinical News

Neurotrope reports mixed Ph III AD data for Bryostatin-1

...<0.07). The trial enrolled 147 patients and also evaluated a 40 μg dose of Bryostatin-1. Neurotrope...
...a secondary endpoint evaluating AD Cooperative Study-Activities of Daily Living-Inventory Severe Impairment Version (ADCS-ADL-SIV) scores, Neurotrope...
...that could lead to efficacy. Bryostatin-1 is a protein kinase C (PKC) epsilon (PKCE) activator. Neurotrope Inc....
Read More
Items per page:
1 - 10 of 36
BioCentury | Feb 22, 2021
Product Development

Otonomy looking beyond Meniere disease after latest Phase III miss

Otonomy will look ahead to a pipeline addressing tinnitus and hearing loss after its latest Phase III failure in Meniere disease.  With Monday’s readout, Otonomy Inc. (NASDAQ:OTIC) shares fell $2.39 (44%) to $3.00, cutting the...
Read More
BioCentury | Oct 4, 2019
Finance

Biotech down again in 3Q19

...Source: Yahoo! Finance The biggest loss among the small calls was the 90% plunge by Neurotrope Inc....
...Editor, Data & Analytics Sarepta Therapeutics Inc. Genmab A/S Galapagos N.V. Nektar Therapeutics Shenzhen Chipscreen Biosciences Ltd. Clovis Oncology Inc. Opthea Ltd. Transgene S.A. Neurotrope Inc. Deciphera...
Read More
BioCentury | Sep 9, 2019
Clinical News

Sept. 9 Clinical Quick Takes: Translate to discontinue enzyme deficiency candidate; plus Janssen, Neurotrope, AMT and Cassava

...in Denmark. Spravato is approved for treatment-resistant depression. Neurotrope plummets on Phase II Alzheimer’s failure Neurotrope Inc....
...kinase C ε Sandi Wong, Staff Writer MRT5201 PTI-125 Spravato, esketamine (jnj-54135419) Synthetic Bryostatin-1 Applied Molecular Transport LLC Cassava Sciences Inc. Janssen Johnson & Johnson Neurotrope Inc. Translate...
Read More
BioCentury | Feb 28, 2018
Distillery Therapeutics

Autoimmune disease

...models of MS and seeking industry partners to test the compound in progressive MS patients. Neurotrope Inc....
...testing to treat Alzheimer’s disease and preclinical testing to treat Niemann-Pick disease type C (NPC). Neurotrope...
Read More
BioCentury | Feb 23, 2018
Emerging Company Profile

Cutting viruses

Armed with a suite of CRISPR nucleases and multiple guide RNAs, Excision BioTherapeutics Inc. is using gene editing to cut out integrated latent viruses from host genomes. The newco is starting with HIV, but has...
Read More
BioCentury | Feb 1, 2018
Preclinical News

Zika-related viruses could also lead to fetal demise

In a study published in Science Translational Medicine , researchers at Washington University School of Medicine in St. Louis and colleagues found that two Zika-related viruses infected human placental explants and led to fetal demise in...
Read More
BioCentury | Dec 20, 2017
Company News

Management tracks: Intellia, Spectrum

...Hamilton as CEO. He succeeds Gary Jacob, who will serve as executive chairman. Neurology company Neurotrope Inc....
Read More
BioCentury | Oct 17, 2017
Distillery Techniques

Chemistry

...and 1.4 nM. Next steps include using the method to synthesize additional undisclosed bryostatin-1 analogs. Neurotrope Inc....
...to treat Alzheimer’s disease and in preclinical testing to treat Niemann-Pick disease type C (NPC). Neurotrope...
...kinase C (PKC) modulator bryostatin-1 and its analogs LICENSING STATUS: Patent application filed; licensed to Neurotrope Inc....
Read More
BioCentury | Jun 5, 2017
Clinical News

Zika virus hijacks neurodevelopmental protein to replicate

In a paper published in Science , University of Cambridge researchers show the Zika virus hijacks neurodevelopmental protein Musashi RNA-binding protein 1 (MSI1) in neural stem cells, increasing viral replication and preventing neural stem cell function....
Read More
BioCentury | May 5, 2017
Clinical News

Neurotrope reports mixed Ph III AD data for Bryostatin-1

...<0.07). The trial enrolled 147 patients and also evaluated a 40 μg dose of Bryostatin-1. Neurotrope...
...a secondary endpoint evaluating AD Cooperative Study-Activities of Daily Living-Inventory Severe Impairment Version (ADCS-ADL-SIV) scores, Neurotrope...
...that could lead to efficacy. Bryostatin-1 is a protein kinase C (PKC) epsilon (PKCE) activator. Neurotrope Inc....
Read More
Items per page:
1 - 10 of 36